anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides a heteromyeloma cell other than B6B11, capable of producing a trioma cell when fused with a human lymphoid cell, wherein the trioma cell is capable of producing a tetroma cell capable of producing a monoclonal antibody having specific binding affinity for an antigen, when fused with a second human lymphoid cell, the second human lymphoid cell being capable of producing antibody having specific binding affinity for the antigen. The invention provides a trioma cell fusion partner which does not produce any antibody obtained by fusing a heteromyeloma cell which does not produce any antibody with a human lymphoid cell. The invention provides a tetroma cell capable of producing a monoclonal antibody having specific binding affinity for an antigen obtained by fusing a trioma cell which does not produce any antibody with a human lymphoid cell capable of producing antibody having specific binding affinity for the antigen. The invention provides a method of producing a monoclonal antibody specific for an antigen associated with a condition. The invention provides a method of identifying an antigen associated with a condition using the trioma fusion partner. The invention provides a method of diagnosing a condition using the trioma fusion partner. The invention provides a method for preventing a condition. Compositions and therapeutic compositions are also provided, using monoclonal antibodies produced using the trioma fusion partner.
Thoracolumbar interfascial plane block (TLIPB)and erector spinae plane block (ESPB) and have been shown to provide effective analgesia after spinal surgery. ESPB targets ventral and dorsal rami of the spinal nerve and also spreads over the paravertebral and epidural space. However, TLIPB targets only dorsal rami of the spinal nerve and spare ventral rami which may provide early ambulation. In addition, depositing local anesthetic in the fascial planes may prevent intraoperative washout. It may translate to an increase in the quality of analgesia. On the other hand, pain is an incomplete measure of postoperative recovery. No study to date has compared these two blocks in terms of the quality of recovery after major spinal surgery. This study will test the hypothesis that patients receiving TLIPB have higher QoR-40 scores in comparison with patients receiving ESPB.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to veterinary gynaecology. A preparation for treating acute postnatal endometritis in cows involves antimicrobial and antiprotozoal agents, and as the antimicrobial agent the preparation contains enrophlone, as the antiprotozoal agent - trichopol (metronidazole), in addition, the preparation contains DMSO, sodium hydroxide and distilled water in the following proportions, g/l of the solution: enrophlone 8.0-12.0; trichopol (metronidazole) 4.0-6.0; DMSO 150.0-250.0; sodium hydroxide pH 10-11; distilled water - the rest. The method of treating acute postnatal endometritis consists in introduction of the specified preparation 50-100 ml once a day for 3-5 days. ^ EFFECT: invention provides higher clinical effectiveness. ^ 2 cl, 2 ex
Breathing support with High-Flow oxygen therapy, flow will be initiated between 50 and 60 liters / minute. FiO2 60% to 100% with the objective of reaching SpO2 ≥ 92%. Adequate wetting of the system should be ensured according to the recommendations of the HFNC device manufacturer. FiO2 may be decreased gradually according to the patient's individual condition, trying to maintain SpO2 ≥ 92%.
INTRODUCTION: Although inflammation is closely associated with the pathogenesis of intracranial aneurysm (IA), detailed causal associations remain unclear. This study aimed to investigate the causality between circulating inflammatory molecules (IMs) and IA.
MATERIALS AND METHODS: The bi-directional Mendelian randomization (MR) analysis was conducted using two genome-wide association studies (GWAS) for inflammatory molecules (IMs) from Finnish and Icelandic populations, as well as GWAS datasets of IA cases and controls of European descent. Colocalization analysis was performed to validate MR associations. Subsequently, Venn analysis was conducted to identify the overlapped causalities.
RESULTS: Integrating the findings from two MR models, RANTES was suggestively associated with IA (Finnish model: inverse variance-weighted odds ratio [ORIVW] (95% confidence interval [95% CI]), 0.86 (0.74-0.99); Icelandic model: 0.80 (0.68-0.94)) and aneurysmal subarachnoid hemorrhage (aSAH) (ORIVW (95% CI): 0.81 (0.68-0.95) and 0.80 (0.66-0.97) in Finnish and Icelandic models). IA and its subtypes were not associated with any of candidate IMs. However, colocalization analysis failed to identify significant evidence of shared genetic instruments between the exposures and outcomes, except for the MCP3-aSAH pair in the Icelandic model.
CONCLUSIONS: No significant causality was identified between IMs and IA or their subtypes. RANTES is potentially associated with IA and aSAH. Further investigation is warranted to explore the role of IMs in IA development.
Participants complete Lumosity cognitive exercises. Lumosity cognitive exercises are online video game-based activities that are designed to practice various cognitive skills including processing speed, attention, memory and executive function. Participants complete cognitive exercises at least 20 minutes a day, 5 days a week for 6 weeks. Participants also complete relaxation exercises (guided imagery, progressive muscle relaxation, and/or autogenics) at least 10 minutes a day for 6 weeks and compensatory strategies (the use of external devices such as a notebook, day planner, or smartphone for cuing, reminding, and organizing; the use of memory strategies such as repetition, paraphrasing, and active listening; and the use of executive strategies such as self-talk for planning and attention orientation) as much as possible.
The molecular mechanisms by which FoxO transcription factors mediate diametrically opposite cellular responses, namely death and survival, remain unknown. Here we show that Mst1 phosphorylates FoxO1 Ser209/Ser215/Ser218/Thr228/Ser232/Ser243, thereby inhibiting FoxO1-mediated transcription of proapoptotic genes. On the other hand, Mst1 increases FoxO1-C/EBP-β interaction and activates C/EBP-β by phosphorylating it at Thr299, thereby promoting transcription of prosurvival genes. Myocardial ischemia/reperfusion injury is larger in cardiac-specific FoxO1 knockout mice than in control mice. However, the concurrent presence of a C/EBP-β T299E phospho-mimetic mutation reduces infarct size in cardiac-specific FoxO1 knockout mice. The C/EBP-β phospho-mimetic mutant exhibits greater binding to the promoter of prosurvival genes than wild type C/EBP-β. In conclusion, phosphorylation of FoxO1 by Mst1 inhibits binding of FoxO1 to pro-apoptotic gene promoters but enhances its binding to C/EBP-β, phosphorylation of C/EBP-β, and transcription of prosurvival genes, which stimulate protective mechanisms in the heart.
Accidental intravascular injection of Ultacan® or Ultacan® forte may be associated with convulsions, followed by central nervous system or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Dental practitioners who employ local anesthetic agents including Ultacan® or Ultacan® forte should be well versed in diagnosis and management of emergencies that may arise from their use. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. To avoid intravascular injection, aspiration should be performed before Ultacan® or Ultacan® forte is injected. The needle must be repositioned until no return of blood can be elicited by aspiration. Note, however, that the absence of blood in the syringe does not guarantee that intravascular injection has been avoided.

Small doses of local anesthetics injected in dental blocks may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injections of larger doses. Confusion, convulsions, respiratory depression or respiratory arrest, and cardiovascular stimulation or depression have been reported. These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. Patients receiving these blocks should be observed constantly. Resuscitative equipment and personnel for treating adverse reactions should be immediately available. Dosage recommendations should not be exceeded [see Dosage and Administration (2.1)].
PURPOSE: To obtain the subject preparation containing, as active ingredient, each specific Corydalis decumbens extract and Eschscholzia californica extract in specified proportions, excellent in efficacy sustainability, and useful for treating e.g. depression, Parkinson's disease. CONSTITUTION: This therapeutic preparation contains, as active ingredient, Corydalis decumbens extract and Eschscholzia californica extract in the weight ratio of (20:1) to (1:1) together with, as circumstances require, conventional additive(s). These extracts, which are afforded by alcohol extraction (2.5:10) as an aqueous and/or alcohol solution, is pref. in the form of powder. It is preferable that the daily dose of the active ingredient is 2-5 mg/kg body weight.
subjects will be allocated according to the inclusion and exclusion criteria from different schools for visually impaired children. They will be divided randomly into study group and control group. Study group will be participated in suboccipital muscle energy technique. Control group will be participated in sham technique. The duration of treatment for both groups will be 3 times/week for 6 weeks. Autodesk AutoCAD software will be used to analyze the measured angles and CROM will be used to assess cervical mobility
The ε4 allele of the APOE gene heightens the risk of late onset Alzheimer's disease. ε4 carriers, may exhibit cognitive and neural changes early on. Given the known memory-enhancing effects of physical exercise, particularly through hippocampal plasticity via endocannabinoid signaling, here we aimed to test whether a single session of physical exercise may benefit memory and underlying neurophysiological processes in young ε3 carriers (ε3/ε4 heterozygotes, risk group) compared with a matched control group (homozygotes for ε3). Participants underwent fMRI while learning picture sequences, followed by cycling or rest before a memory test. Blood samples measured endocannabinoid levels. At the behavioral level, the risk group exhibited poorer associative memory performance, regardless of the exercising condition. At the brain level, the risk group showed increased medial temporal lobe activity during memory retrieval irrespective of exercise (suggesting neural compensatory effects even at baseline), whereas, in the control group, such increase was only detectable after physical exercise. Critically, an exercise-related endocannabinoid increase correlated with task-related hippocampal activation in the control group only. In conclusion, healthy young individuals carrying the ε4 allele may present suboptimal associative memory performance (when compared with homozygote ε3 carriers), together with reduced plasticity (and functional over-compensation) within medial temporal structures.
Transgender and gender diverse (e.g., gender non-binary) (TGD) individuals remain a hidden group in the Central Eastern European (CEE) country of Romania, with few protections, few equal rights, and many unmet needs. Emerging research with TGD persons in the region indicates that TGD Romanians report particularly high rates of HIV, depression, and hazardous alcohol use, primarily driven by the country's high structural stigma. Romania's healthcare system has little expertise for addressing these syndemic health threats. No targeted needs assessments or interventions exist to date in order to remedy these adversities and promote the wellbeing of TGD in Romania, or anywhere in CEE - the region with the fastest-growing HIV epidemic in the world. In response, the investigators propose to create and pilot-test the first intervention in CEE to address the sexual, mental, and behavioral health of TGD people. In Aim 1, the investigators will identify unique needs of TGD Romanians via interviews. Findings will be used in Aim 2 to modify an intervention manual to address gender minority stress and other TGD-specific determinants of mental health, hazardous alcohol use, and HIV risk. The intervention will be based on a Romanian-adapted EQuIP (Empowering Queer Identities in Psychotherapy) intervention d developed and successfully tested by our team in several global regions (e.g., the U.S., China). In Aim 3, the investigators will evaluate the adapted intervention's feasibility, acceptability, and efficacy potential in a one-arm trial with 25 TGD Romanians. By extending the intervention research to at-risk TGD populations, the investigators will ensure more equitable access to the interventions and embed them within a national infrastructure increasingly eager for and capable of reaching the full diversity of the Romanian LGBTQ population to address its currently unmet needs.
Both arms will undergo 8-weeks of Mindfulness-Based Stress Reduction (MBSR) training. The active comparator arm will be randomly assigned to not practice meditation, but rather listen to a non-meditative audio track of equal length, immediately following the emotional stress task in the lab during the post-MBSR lab visit.
Background: The use of cannabis and its perceived safety among pregnant and breastfeeding women has increased in the context of expanding legalization. Current guidelines recommend abstaining from the use of cannabis while pregnant or breastfeeding due to the potential for harm, although there is still much that is unknown in this field. Case Presentation: A 5-week-old infant presented with recurrent apneic episodes and a positive urine delta-9-tetrahydrocannabinol (THC) screening test. The infant's mother reported regular cannabis use for treatment of depression and anxiety while pregnant and breastfeeding. The infant was subsequently transitioned to formula feedings, and the infant's condition improved. Conclusion: Cannabis and its active metabolites can be transferred into breast milk and may have deleterious neurologic effects on infants. However, a causal relationship between cannabis exposure and short- or long-term neurologic sequelae has not yet been definitively established. Further studies are warranted to assess the safety of maternal cannabis use for breastfed infants.
PURPOSE:An antiviral agent having activity against influenza virus, usable safely, containing antibiotic SF-2140 substance as an active component. CONSTITUTION:An antiviral agent containing antibiotic SF-2140 substance shown by the formula as an active ingredient. SF-2140 substance is a substance identical to an antibiotic collected from a culture solution of Actinomadura sp. SF- 2140 (FERM-P 5704) discovered before. This substance is newly found to have antiviral activity. For example, it has high antiviral action on influenza virus. This agent is preferably used as an oral agent. A dose is 0.05-25g/persion 2- 4 times daily.
Patients receive panitumumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium PO, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
The invention relates to a calcipotriol beta-cyclodextrin inclusion compound and a preparation method thereof. The inclusion compound comprises 4.5%-21% of calcipotriol. The preparation method comprises step of adding one volume of 0.3mol/L calcipotriol ethanol solution into 15-20 volumes of 0.012-0.016mol/L beta-cyclodextrin aqueous solution for clathration. The preparation method finally prepares the calcipotriol inclusion compound meeting the requirement of medicines in grain size and uniformity. The inclusion compound can be further prepared into cream, ointment and suspension solution. Compared with non-covered calcipotriol, the calcipotriol beta-cyclodextrin inclusion compound and the preparations prepared from the inclusion compound are remarkably improved in stability, and the problem of uneven content caused by trace feeding capacity is solved.
This is a randomized, un-blinded, Phase II study in males and non-pregnant females, who are in good health, 19 to 64 years of age. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of a pre-pandemic AS03 (GSK) adjuvanted 2017 monovalent inactivated influenza A/H7N9 vaccine (2017 H7N9 IIV) manufactured by Sanofi Pasteur (3.75 mcg of HA per dose with Phosphate Buffered Saline (PBS) diluent), when two doses are administered 21 days apart either sequentially or simultaneously (within 15 minutes) with licensed seasonal influenza vaccine. Subjects will be randomized into one of three treatment groups. Group 1 will receive two doses of AS03-adjuvanted 2017 H7N9 IIV, each dose administered IM approximately 21 days apart, and one dose of licensed seasonal IIV4 will be administered IM simultaneously (within 15 minutes) with the first dose of AS03 adjuvanted 2017 H7N9 IIV. Group 2 will receive one dose of IIV4 approximately 21 days prior to the IM administration of two doses of AS03-adjuvanted 2017 H7N9 IIV; each dose of AS03-adjuvanted 2017 H7N9 IIV will be given approximately 21 days apart. Group 3 will receive one dose IM of IIV4 as an un-blinded comparator. The study will enroll approximately 150 individuals who have no history of influenza A/H7N9 infection or prior receipt of an influenza virus H7 subtype vaccine. Study duration is approximately 16 months with subject participation duration of approximately 13 months. The primary objectives of this study are: 1) to assess the safety and reactogenicity following sequential or simultaneous IM administration of 2 doses of AS03-adjuvanted 2017 H7N9 IIV and one dose of seasonal influenza vaccine (IIV4); 2) to assess the serum HAI and Neut antibody responses against A/H7N9 at approximately 21 days following receipt of two doses of AS03-adjuvanted 2017 H7N9 IIV administered IM approximately 21 days apart; 3) to assess the serum HAI and Neut antibody responses against the seasonal influenza strains at approximately 21 days following receipt of IIV4. The secondary objectives are: 1) to assess unsolicited non-SAEs following sequential or simultaneous IM administration of AS03-adjuvanted 2017 H7N9 IIV and seasonal influenza vaccine (IIV4); 2) to assess MAAEs, including NOCMCs and PIMMCs, following sequential or simultaneous IM administration of AS03-adjuvanted 2017 H7N9 IIV and IIV4; 3) to assess the HAI and Neut antibody responses at 21 days following receipt of 1 dose of AS03-adjuvanted 2017 H7N9 IIV.
<P>PROBLEM TO BE SOLVED: To provide an image display device by which a data file of medical images picked-up from a large number of subjects is easily retrieved and displayed.   <P>SOLUTION: The data file of the medical images picked-up from the large number of subjects is stored together with at least the names of the subjects, and subject IDs. When a sound mode is changed-over and set, an input sound is recognized as at least one of the subject name and the subject ID, the one data file is retrieved with the recognition result as a retrieval key, and, then, the medical image is displayed. When at least one of the subject name and the subject ID is inputted as the sound, a retrieval is performed even in the case of the large amount of data file. Thus, it is not necessary to conduct a complicated work that text data of the subject name or the subject ID is inputted with a keyboard.  <P>COPYRIGHT: (C)2004,JPO
Inflammatory skin diseases are increasingly common in various industrialized western societies. In 2015, eczema or dermatitis, the most common inflammatory skin disease, is estimated to have affected 245 million people worldwide. In fact, the biggest percentage of cases seen in National Skin Centre (NSC), Singapore is for dermatitis (34.1%) while other inflammatory skin diseases such as contact dermatitis and psoriasis account for 4.7% and 3.3% of the cases respectively. Inflammatory skin diseases can cause remodeling of the vasculature. This vascular remodeling is brought about by the imbalance between pro- and anti-angiogenic mediators under conditions of chronic inflammation, resulting in either vessel growth or recession. Vascular remodeling of affected skin usually display vascular enlargement during inflammation. In psoriasis, for example, the skin capillaries expand and become tortuous, making the lesions appear red due to the thinned epithelium.

Emerging evidence reports that chronic inflammatory skin diseases are closely related to systemic complications such as atherosclerosis, type 2 diabetes or metabolic syndrome due to systemic inflammation. One possible theory linking cutaneous and systemic vascular diseases is from the release of products such as inflammatory cytokines produced in affected skin lesions into the systemic circulation, resulting in the increased risk of inflammation in other organs or tissues. It was reported that individuals with Atopic Dermatitis (AD) in the adult US population tend to have a self-reported history of hypertension and adult-onset diabetes even with control of body mass index and other comorbidities. An analysis of different studies indicated that both individuals from Asia and North America with pediatric and adult-onset of AD have a higher chance of being overweight, which can lead to other metabolic diseases. It was also reported that there is an increased number of inflammatory cells around vessels seen in histopathology biopsies of the human forearm skin for diabetic patients compared to non-diabetic populations. The density of vascular network also tended to be higher in diabetic patients in the forearms compared to non-diabetic subjects. However, no difference in vascular networks were observed between subjects with Type 1 and Type 2 diabetes. The mechanism to explain the increased vessel density in diabetic subjects is not known, though inflammation plays a role due to the presence of inflammatory cells. Since inflammatory skin diseases are systemic disorders due to the co-morbidities, it would shed light on the understanding of these diseases and their linkages to metabolic disease such as diabetes.
Vegetable pigments which are vitamin P factors are extracted from plants contg. them, especially the leaves, by macerating the plants in water containing an antioxidant and antiseptic for 15-45 minutes at 70-75 degrees C, cooling to 15-55 degrees C and recovering the solution containing the pigments, concentrating and opt. purifying the powder thus obtd. The pigments are effective against vein and capillary fragility, high arterial pressure, and have a beneficial effect on smooth muscle (e.g. the heart) respiration, bile flow, transpiration, diuresis, etc. The plants used are pref. vine leaves, esp. the autumn leaves of dark red grapevines. These are macerated, but not too finely or difficulties result from liberation of gums and pectin. The antioxidant and antiseptic is pref. SO2 and about 2-3 litres of water are used per kg of plant. Concn. of the resultant soln. is pref. effected at 40-50 degrees C/5-10 mm Hg. The product comprises the monglucosides of malvidol, paeonidol, petrunidol, and delphinidol and also flavonols. The yield is about 20 kg pigments per kg fresh leaves.